After a Volatile Run, Here's the Honest Buy, Sell, or Hold on 3M

3M has risen nearly 70% over the past three years, but remains down 11% over five years and about 15% below its 52-week high. The company’s adjusted earnings increased 10% in 2025 and nearly 14% in Q1 2026, while the dividend yield stands at 2.1% and the payout has already been raised twice since a 2024 reduction. However, ongoing litigation tied to military earplugs and PFAS remains a major overhang, keeping the stock volatile despite the Solventum spin-off.

Analysis

MMM is transitioning from a classic “quality industrial” to a litigation-driven cash yield story, and that changes the investor base more than the earnings profile. The market is likely underpricing how long legal overhang can suppress multiple expansion even if operating performance stays solid: when headline EPS is partially manufactured by excluding litigation, the stock trades like a bond proxy only until the next adverse procedural update forces de-rating.

The cleaner second-order beneficiary is SOLV. The separation removes the slowest-to-underwrite tail risk from MMM’s multiple, while SOLV inherits a more focused healthcare asset base with less conglomerate discount but also less hidden subsidy from the parent. That creates a divergence setup: MMM can rerate on reduced uncertainty, but SOLV may outperform on cleaner fundamentals if investors stop treating it as a leftover stub and start valuing it on healthcare peers.

The key contrarian point is that consensus is framing MMM as “cheap because durable,” when the more relevant question is whether the dividend and buyback capacity are now hostage to litigation timing rather than industrial demand. In that regime, the stock can grind higher for quarters and still underperform on a risk-adjusted basis because every incremental dollar of cash return is offset by an embedded legal put. Any disappointment in settlement cadence, reserve disclosure, or incremental exclusion from adjusted earnings is a catalyst for fast multiple compression over days, not years.

Key Decisions for Investors

• Avoid initiating fresh long MMM here; if already long, sell upside calls or run a collar into the next legal headline window to monetize yield while capping litigation-driven drawdowns.
• Relative-value long SOLV / short MMM for a 3-6 month horizon: the spread should benefit if investors continue to reward cleaner standalone healthcare earnings over litigation-contaminated industrial cash flows.
• If you want industrial beta, prefer a basket long in cleaner cyclicals over MMM; the setup is poor for owning a stock whose reported earnings quality remains partially adjusted away.
• For event-driven accounts, buy MMM puts 2-4 months out on strength rather than weakness; implied volatility should stay elevated, and the main downside catalyst is an adverse or opaque legal update rather than an earnings miss.